Search - tctmd.com

Displaying 1 - 20 of 57

Sort: Relevancy | Date

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

L.A. McKeown

September 05, 2025

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

L.A. McKeown

November 06, 2024

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

News Daily News

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

L.A. McKeown

April 24, 2024

News Daily News

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

L.A. McKeown

March 25, 2024

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

News Daily News

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

L.A. McKeown

July 11, 2023

News Conference News LINC 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

L.A. McKeown

June 21, 2023

News Daily News

Only Half of Revascularized PAD Patients Receive GDMT

L.A. McKeown

February 14, 2023

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Daily News

Top Endovascular News of 2022

L.A. McKeown

January 03, 2023

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

L.A. McKeown

November 07, 2022

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Daily News

MOSAIC: Home Intervention Boosts Walking Time in PAD Patients

L.A. McKeown

April 15, 2022

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

L.A. McKeown

April 04, 2022

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

L.A. McKeown

May 16, 2021

News Daily News

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

L.A. McKeown

April 22, 2021

News Daily News

No Paclitaxel Death Signal in VA Data Out to 3 Years

L.A. McKeown

February 11, 2021

Advertisement

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

Only Half of Revascularized PAD Patients Receive GDMT

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Top Endovascular News of 2022

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

MOSAIC: Home Intervention Boosts Walking Time in PAD Patients

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

No Paclitaxel Death Signal in VA Data Out to 3 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content